臨床薬理の進歩 No.46

19/216

(etarecnetssreptnemtaerT5)%i005 2510050log-rank p= 0.0002No cATBcATB1015Time (y)20p-value0.0030.0530.001表2　抗菌薬の種類ATB classCephalasporinsSulfonamides + TrimethoprimMetronidazoleFluoroquinolonesPenicillin + BLIsTetracyclinesMacrolidesPenicillinsGlycopeptidesAminoglycosidesCarbapenemsOthersAbbreviations: ATB, antibacterials; BLI; β-lactamase inhibitor,cATB, concurrent antibacterial therapy; pATB, prior antibacterial therapy表3　抗体医薬品の治療失敗リスクに関する多変量ロジスティック回帰分析CharacteristicSex Male FemaleAge, y <65 >=65pATB No YescATB No YesAbbreviations: cATB, concurrent antibacterial therapy; CI, confidential interval;OR, odds ratio; pATB, prior antibacterial therapy図1　 抗体医薬品の治療継続率に及ぼす抗菌薬併用の影響cATB, concurrent antibacterial therapyp値：log-rank検定pATB No. (n = 36)20041142423033cATB No. (n = 79)2622121276752106Multivariate analysisp-valueOR (95% CI)1 [Reference]3.00 (1.44–6.26)0.0041 [Reference]1.83 (0.99–3.38)0.0260.1981 [Reference]3.12 (1.64–5.96)0.001抗体医薬品のPK-ADA解析を基盤とした治療最適化に資するリアルワールドエビデンスの創出Univariate analysisOR (95% CI)1 [Reference]2.88 (1.40–5.91)1 [Reference]1.96 (1.08–3.55)1 [Reference]1.78 (0.74–4.31)1 [Reference]2.88 (1.54–5.38)